Global law firm Dentons, at the request of Cedric Law, advised Vitrolife AB - a Swedish headquartered multinational focused on medical devices for in vitro fertilization (IVF) – on the acquisition of 100% of the share capital in Igenomix for €1,25 billion from  EQT Fund, Charme Capital Partners and other shareholders.  Igenomix is a global leader in women’s health and reproductive genetic testing services for IVF clinics.   

The combination will create a global leader in reproductive health by combining the Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s IVF device portfolio, as well as the complementary knowledge and market presence of the two companies.

Nieves Briz, Barcelona Managing Partner, led the deal with a multi-competency, cross-border Dentons team.  She was supported by partner Jesus Duran and counsel Natalia Ontiveros. Associate Gabriel Mendez, junior associates Daniel Seculi and Angela de la Iglesia in Barcelona and senior associates Iñigo Olarte and Adrien Coispel, counsel Juan Alonso Berberena, and junior associates Sara Moukayed and Blanca Stolzenburg in Madrid performed the due diligence.  Partner Michele Carpagnano (Rome) and associates Paloma Hurtado (Madrid) and Giulia Giordano (Rome) advised on competition law matters, including merger control and foreign direct investment (FDI) screening, with input from Dentons colleagues across 24 jurisdictions.

Lazard acted as financial adviser and Olof Thorsell from Cedric Law acted as legal adviser to Vitrolife AB.